1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Empyrean Therapeutics acquires TLR-2 antagonist molecule from Eos Therapies

28 Nov 2024
Admin
News Article

Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies

Empyrean Therapeutics acquires TLR-2 antagonist molecule from Eos Therapies to advance and commercialize breakthrough cancer treatment

Overview

Empyrean Therapeutics, Inc., a pioneering biopharmaceutical company, announced the successful acquisition of a first-in-class novel TLR-2 antagonist molecule from Eos Therapies, Inc. This strategic move aims to accelerate the development of a new, safe, and effective cancer drug targeting brain, pancreatic, breast, and other hard-to-treat cancers. Designated EMS-312, it is currently in the pre-investigational new drug (pre-IND) phase and is being readied for comprehensive in vivo validation. Empyrean Therapeutics plans to leverage its robust research and development infrastructure and global luminary network to expedite the molecule’s progression toward in-human clinical trials and market launch.

Words from the CEO: Empyrean Therapeutics

“This acquisition marks a significant milestone for Empyrean Therapeutics,” said Kal Fishman, CEO of Empyrean Therapeutics.
“Our EMS-312 small molecule exhibits excellent target affinity, potency, drug-like properties, oral bioavailability, brain uptake, efflux pump avoidance, and it satisfies lead criteria. We are thrilled to integrate it into our pipeline and are committed to advancing it swiftly through the development phases. Our goal is to offer new hope to patients worldwide who are battling some of the most aggressive forms of cancer.”

Words from the CEO: Eos Therapies

Doug Bonhaus, PhD, CEO of Eos Therapies, said: “We are very pleased to have completed this transaction with Empyrean Therapeutics, and we look forward to seeing this promising therapeutic candidate advance as a potential first-in-class new treatment for cancer.”

About the Transaction

Eos Therapies and Empyrean Therapeutics completed the transaction in October 2024.
The EMS-312 molecule has been recently granted patents in all major global markets.
Both companies collaborate closely to seamlessly transition all intellectual property, associated research data, and compound materials to Empyrean Therapeutics’ labs at the Center for Novel Therapeutics in La Jolla, California.

About Empyrean Therapeutics, Inc.

Empyrean Therapeutics, Inc. is dedicated to transforming the landscape of cancer treatment through the development of groundbreaking therapies.
Its mission is to harness the power of innovative science to create life-changing medications for patients facing the toughest cancers.

About Eos Therapies

Eos Therapies is a San Diego-based company focused on the discovery and clinical development of small molecule Toll-Like Receptor (TLR) antagonists for the treatment of Parkinson’s disease and other neurodegenerative disorders.